Clinical Trial Update: Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating switching to aflibercept 8 mg for patients with age-related macular degeneration who have shown limited response to prior…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Kim's Eye Hospital | Conditions: Age-related Macular Degeneration (ARMD) | Phase 4 | Status: RECRUITING